Your session is about to expire
← Back to Search
CC-486 for Non-Small Cell Lung Cancer (abound2L+ Trial)
abound2L+ Trial Summary
This trial will test the effectiveness of two different drugs, either alone or in combination, as a second or third line of treatment for advanced non-small cell lung cancer.
- Non-Small Cell Lung Cancer
abound2L+ Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 240 Patients • NCT02250326abound2L+ Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You do not have any other cancer that needs to be treated.You have a history of lung diseases, including interstitial lung disease.You have received a specific type of immunotherapy called anti-PD-1 or anti-PD-L1 in the past.You received a live vaccine within 30 days before the first dose of the study drug.Your disease cannot be measured at the beginning of the study.You have had an allergic reaction in the past to the study drug or any of its ingredients.You have any other important medical condition, mental illness, or problems with your organs.You have received an organ transplant from someone else in the past.You have a medical condition that could make it difficult to understand or analyze the study results.Male patients who are not willing to use effective birth control.You had another type of cancer within the last 5 years before starting this study.You have received radiation therapy within the last 4 weeks or limited radiation therapy for pain relief within the last 2 weeks before starting the investigation product.
- Group 1: Monotherapy arm: nab-paclitaxel IV infusion
- Group 2: Combination arm: nab-paclitaxel and CC-486
- Group 3: Nab-paclitaxel and Durvalumab combination
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the opportunity for enrollment in this trial extant?
"Confirmed. Data from clinicaltrials.gov reveals that this medical trial, initially posted on July 1st 2015, has completed its recruitment process and is no longer searching for potential patients. Notwithstanding, there are still 2,912 other active studies in need of volunteers at the present time."
What is the safety profile associated with CC-486?
"Considering the Phase 2 status of CC-486, our team at Power assigned it a safety rating of two. This is based on evidence that supports its security but no current data suggesting effectiveness."
Are there any restrictions as to the number of participants in this experiment?
"Unfortunately, this study has ceased accepting new patients. It was initially posted on July 1st 2015 and had its most recent update on January 24th 2022. However, if you are in search of other medical studies for your condition, there currently exist 1908 clinical trials enrolling individuals with carcinoma non-small cell lung and 1004 studies recruiting participants who use CC-486 medication."
Is there precedent for the implementation of CC-486 in medical research?
"CC-486 was initially studied at City of Hope Comprehensive Cancer Center in 1997. Since then, it has been the focus of a whopping 1,301 completed clinical trials with many still ongoing out of New york. Currently, there are 1004 active studies involving this medication."
How many sites are actively engaged with this research project?
"This research trial is currently enrolling at 11 medical sites. These include New york, Hackensack and Chattanooga as well as other cities in the USA. Patients should aim to select a centre close by them in order to reduce travel burdens if they decide to join the study."
To which ailments is CC-486 usually prescribed?
"CC-486 is available to combat anemia and can also effectively treat numerous other conditions, such as advanced non-small cell lung cancer, metastatic bladder cancer, and complete blood count."
Share this study with friends
Copy Link
Messenger